Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.28 (
chloramphenicol acetyltransferase
)
5,100
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
PKN
is a fatty acid-activated serine/threonine protein kinase, having a catalytic domain homologous to protein kinase C family.
PKN
has been recently reported to interact with a small GTP-binding protein Rho and cytoskeletal proteins such as neurofilament and alpha-actinin. To identify the new components of the
PKN
-signaling pathway, the yeast two-hybrid system was employed. Using the amino-terminal regulatory domain of
PKN
as a bait, cDNA encoding a neural antigen PCD17, which is recognized by characteristic antibodies of patients with paraneoplastic cerebellar degeneration, was isolated from a human brain cDNA library. The interaction between
PKN
and PCD17 was also determined by the in vitro binding analysis. PCD17 was coimmunoprecipitated with
PKN
from the lysate of COS7 cells transfected with both expression constructs for
PKN
and the amino-terminal region of PCD17. PCD17 was phosphorylated by
PKN
, and the extent of this phosphorylation was enhanced by addition of 40 microM arachidonic acid. The amino-terminal region of PCD17 could form a homodimer in vitro, and PCD17 fused to the Gal4 DNA binding domain showed the transcriptional transactivation of the
chloramphenicol acetyltransferase
reporter gene linked to 5 Gal4 binding sites and minimal promoter in rat C6 glioma cells. These results suggest the participation of PCD17 in gene expression and lead to a clue for elucidating the
PKN
signaling pathway from the cytosol to the nucleus.
...
PMID:PKN interacts with a paraneoplastic cerebellar degeneration-associated antigen, which is a potential transcription factor. 963 78